Ghose K
Eur J Clin Pharmacol. 1980 Aug;18(2):151-17. doi: 10.1007/BF00561583.
A combined pharmacodynamic and pharmacokinetic approach was made to study the pharmacodynamic half-life (Pd1/2) of amitriptyline (AT). Six depressed patients were treated with 150 mg of amitriptyline as a single oral dose at night for six or more weeks. Decreased tyramine sensitivity (DTS), an index of this drug's pharmacological activity, was determined serially at various intervals after the last dose. Plasma concentrations of AT and nortriptyline (NT) were also estimated at above intervals. It was possible to detect DTS for 228-300 h after the last oral dose and the mean Pd1/2 of this decline of pharmacodynamic effect was observed to be 135 h. However, no measurable amount of AT or NT was present after 84 h and the mean elimination plasma half-life (t1/2) of AT and NT were 37.7 and 38.9 h, respectively. (In this study, pharmacokinetic parameters of NT were directly related with those of AT.) Prolonged pharmacodynamic effect of this drug after discontinuation should be borne in mind in order to avoid drug interactions and autonomic complications, especially after overdosage. Pd1/2, as assessed by DTS, correlated directly with the t1/2 (r = 0.91) and inversely with the plasma clearance rate (r = 0.60) of NT. DTS test can be used as an alternative technique to assess the biological activity of a drug which inhibits noradrenaline reuptake mechanism and/or blocks alpha-adrenoceptors at the peripheral neuronal sites, especially, where facilities to measure plasma concentrations of such drugs are limited.
采用药效学和药代动力学相结合的方法研究阿米替林(AT)的药效学半衰期(Pd1/2)。6例抑郁症患者于夜间单次口服150 mg阿米替林,疗程6周或更长时间。酪胺敏感性降低(DTS)是该药物药理活性的指标,在最后一剂后的不同时间间隔连续测定。同时在上述时间间隔估算血浆中AT和去甲替林(NT)的浓度。最后一次口服给药后228 - 300小时可检测到DTS,观察到药效学效应下降的平均Pd1/2为135小时。然而,84小时后未检测到可测量的AT或NT,AT和NT的平均血浆消除半衰期(t1/2)分别为37.7小时和38.9小时。(本研究中,NT的药代动力学参数与AT直接相关。)停药后该药物药效学效应延长,应牢记这一点以避免药物相互作用和自主神经并发症,尤其是过量用药后。通过DTS评估的Pd1/2与NT的t1/2直接相关(r = 0.91),与NT的血浆清除率呈负相关(r = 0.60)。DTS试验可作为一种替代技术,用于评估抑制去甲肾上腺素再摄取机制和/或在外周神经元部位阻断α - 肾上腺素能受体的药物的生物活性,特别是在测量此类药物血浆浓度的设备有限的情况下。